4.4 Article

Laser-Evoked Potentials Habituation in Fibromyalgia

Journal

JOURNAL OF PAIN
Volume 12, Issue 1, Pages 116-124

Publisher

CHURCHILL LIVINGSTONE
DOI: 10.1016/j.jpain.2010.06.004

Keywords

Fibromyalgia; laser-evoked potentials; habituation

Funding

  1. Italian Ministry for Universities and Research [protocol 20089CZ48N_003]

Ask authors/readers for more resources

Abnormalities of central pain processing play an important role in the pathophysiology of fibromyalgia (FM). The aims of the present study were to: 1) evaluate habituation of laser-evoked potentials (LEP) to repeated painful stimulation of 1 tender and 2 nontender points; and 2) determine correlations between LEP abnormalities and major clinical features of FM. Fourteen consecutive FM outpatients and 13 normal controls were included. LEP were recorded from scalp designations Fz, Cz, Pz, T3, and T4. The dorsum of the right hand, the right supra-orbital zone, and the right knee (a tender point in all patients) were subjected to repeated CO2 laser stimuli. For each stimulation site, recordings were obtained for 3 consecutive series of 20 stimuli. The 3 main findings in FM patients were: 1) an increased amplitude of vertex LEP and subjective laser pain; 2) decreased habituation of vertex LEP and subjective laser pain; and 3) a correlation between reduced N2 wave habituation and the severity of self-reported depressive symptoms. As with other chronic pain syndromes, the pathophysiology of FM may involve a generalized increase in the perception of painful stimuli and reduced habituation of the sensory cortex. Perspective: Reduced habituation of cortical responses to laser stimuli in FM patients suggests alterations in the pattern of cortical excitability. This is facilitated by depressive symptoms and abnormalities in central neurotransmission. These findings provide further support for the use of medications with effects on the central nervous system in the management of FM. (C) 2011 by the American Pain Society

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Rheumatology

European bio-naive spondyloarthritis patients initiating TNF inhibitor: time trends in baseline characteristics, treatment retention and response

Sara Nysom Christiansen, Lykke Midtboll Ornbjerg, Simon Horskjaer Rasmussen, Anne Gitte Loft, Johan Askling, Florenzo Iannone, Jakub Zavada, Brigitte Michelsen, Michael Nissen, Fatos Onen, Maria Jose Santos, Manuel Pombo-Suarez, Heikki Relas, Gary J. Macfarlane, Matija Tomsic, Catalin Codreanu, Bjorn Gudbjornsson, Irene Van der Horst-Bruinsma, Daniela Di Giuseppe, Bente Glintborg, Elisa Gremese, Karel Pavelka, Eirik Klami Kristianslund, Adrian Ciurea, Nurullah Akkoc, Anabela Barcelos, Carlos Sanchez-Piedra, Ritva Peltomaa, Gareth T. Jones, Ziga Rotar, Ruxandra Ionescu, Gerdur Grondal, Marleen G. H. Van de Sande, Karin Laas, Mikkel Ostergaard, Merete L. Hetland

Summary: This study investigated the time trends in baseline characteristics and treatment outcomes of TNF inhibitor (TNFi) treatment in bio-naive axial spondyloarthritis (axSpA) and psoriatic arthritis (PsA) patients. The results showed that over the past decades, clinicians have implemented more aggressive treatment strategies in spondyloarthritis, leading to shorter disease duration at treatment initiation, decreased retention rates, and higher remission rates.

RHEUMATOLOGY (2022)

Review Medicine, General & Internal

Informed consent and biological agents in rheumatology and internal medicine

Gabriele Mandarelli, Florenzo Iannone, Stefano Ferracuti, Ignazio Grattagliano, Marcello Benevento, Biagio Solarino, Davide Ferorelli, Roberto Catanesi

Summary: The study reviewed the literature on biological agents and found that there were no specific studies addressing the issue of informed consent in patients receiving biological agents. However, the association between biological agents and serious infections or malignancies needs to be disclosed in the informed consent process, and ethical and clinical issues related to experimenting with new agents with potential serious adverse effects deserve attention.

EUROPEAN JOURNAL OF CLINICAL INVESTIGATION (2022)

Article Rheumatology

The impact of a csDMARD in combination with a TNF inhibitor on drug retention and clinical remission in axial spondyloarthritis

Michael Nissen, Benedicte Delcoigne, Daniela Di Giuseppe, Lennart Jacobsson, Merete Lund Hetland, Adrian Ciurea, Lucie Nekvindova, Florenzo Iannone, Nurullah Akkoc, Tuulikki Sokka-Isler, Karen Minde Fagerli, Maria Jose Santos, Catalin Codreanu, Manuel Pombo-Suarez, Ziga Rotar, Bjorn Gudbjornsson, Irene Van der Horst-Bruinsma, Anne Gitte Loft, Burkhard Moeller, Herman Mann, Fabrizio Conti, Gozde Yildirim Cetin, Heikki Relas, Brigitte Michelsen, Pedro Avila Ribeiro, Ruxandra Ionescu, Carlos Sanchez-Piedra, Matija Tomsic, Arni Jon Geirsson, Johan Askling, Bente Glintborg, Ulf Lindstroem

Summary: This multicenter study of axSpA patients found similar one-year treatment outcomes between TNFi monotherapy and csDMARD co-therapy. Heterogeneity across countries limited the identification of specific subgroups, such as peripheral arthritis, that may benefit from co-therapy.

RHEUMATOLOGY (2022)

Review Immunology

Subcutaneously-Administered Infliximab in the Management of Rheumatoid Arthritis: A Short Narrative Review of Current Clinical Evidence

Florenzo Iannone, Fabrizio Conti, Alberto Cauli, Alberto Farina, Roberto Caporali

Summary: The subcutaneous formulation of infliximab CT-P13 has been authorized for the treatment of multiple diseases and has shown good efficacy in clinical practice. Compared to intravenous injection, subcutaneous administration has optimized clinical characteristics and practical advantages. However, further research is needed to explore its limitations due to limited clinical experience and lack of long-term drug retention data.

JOURNAL OF INFLAMMATION RESEARCH (2022)

Letter Rheumatology

Sequential rituximab and mepolizumab in eosinophilic granulomatosis with polyangiitis (EGPA): a European multicentre observational study

Alessandra Bettiol, Maria Letizia Urban, Federica Bello, Davide Fiori, Irene Mattioli, Giuseppe Lopalco, Florenzo Iannone, Allyson Egan, Lorenzo Dagna, Marco Caminati, Simone Negrini, Elena Bargagli, Marco Folci, Franco Franceschini, Roberto Padoan, Oliver Flossmann, Roser Solans, Jan Schroeder, Marc Andre, Laura Moi, Paola Parronchi, Dario Roccatello, Savino Sciascia, David Jayne, Domenico Prisco, Augusto Vaglio, Giacomo Emmi

ANNALS OF THE RHEUMATIC DISEASES (2022)

Article Rheumatology

After JAK inhibitor failure: to cycle or to switch, that is the question - data from the JAK-pot collaboration of registries

Manuel Pombo-Suarez, Carlos Sanchez-Piedra, Juan Gomez-Reino, Kim Lauper, Denis Mongin, Florenzo Iannone, Karel Pavelka, Dan C. Nordstrom, Nevsun Inanc, Catalin Codreanu, Kimme L. Hyrich, Denis Choquette, Anja Strangfeld, Burkhard F. Leeb, Ziga Rotar, Ana Rodrigues, Eirik Klami Kristianslund, Tore K. Kvien, Ori Elkayam, Galina Lukina, Sytske Anne Bergstra, Axel Finckh, Delphine Sophie Courvoisier

Summary: The objective of this study was to compare the effectiveness of cycling Janus kinase inhibitors (JAKi) with switching to biologic disease-modifying antirheumatic drug (bDMARD) in patients with rheumatoid arthritis (RA). The results showed that both strategies had similar observed drug retention rates after 2 years, but cycling JAKi was associated with higher retention after adjusting for confounders. It was also found that if the first JAKi was discontinued due to an adverse event (AE), it was more likely that the second JAKi would also be stopped due to an AE. Improvement in Clinical Disease Activity Index (CDAI) over time was similar in both strategies.

ANNALS OF THE RHEUMATIC DISEASES (2023)

Review Rheumatology

Subcutaneous immunoglobulin therapy for refractory skin thickening in rapidly progressive systemic sclerosis: A case report and literature review

Fabio Cacciapaglia, Stefano Stano, Marco Fornaro, Florenzo Iannone

Summary: The use of immunoglobulin has shown efficacy in the treatment of different rheumatologic autoimmune systemic diseases. A study on immunoglobulin therapy for systemic sclerosis showed encouraging results in improving skin symptoms. We present a case of a young woman with rapidly progressive diffuse cutaneous systemic sclerosis who had significant skin improvement after one year of subcutaneous immunoglobulin treatment. A narrative literature review on alternative treatments for systemic sclerosis skin involvement, focusing on immunoglobulin use, was also carried out.

JOURNAL OF SCLERODERMA AND RELATED DISORDERS (2023)

Article Biochemistry & Molecular Biology

Elevated Expression of ADAM10 in Skeletal Muscle of Patients with Idiopathic Inflammatory Myopathies Could Be Responsible for FNDC5/Irisin Unbalance

Roberta Zerlotin, Marco Fornaro, Mariella Errede, Patrizia Pignataro, Clelia Suriano, Maddalena Ruggieri, Silvia Colucci, Florenzo Iannone, Maria Grano, Graziana Colaianni

Summary: In this cohort study, 41 patients with DM and IMNM were examined. The results showed lower expression of FNDC5 in the muscle biopsies of these patients compared to the control group, while serum irisin levels were higher. The authors hypothesize that increased expression of ADAM10 in the skeletal muscle of DM and IMNM patients may be responsible for the discrepancy between irisin levels and FNDC5 expression. Further research is needed to understand the mechanisms underlying exacerbated FNDC5 cleavage and muscle irisin resistance in these inflammatory myopathies.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)

Review Medicine, General & Internal

Axial Spondyloarthritis: Reshape the Future-From the 2022 GISEA International Symposium

Fausto Salaffi, Cesare Siragusano, Alessandra Alciati, Giulia Cassone, Salvatore D'Angelo, Serena Guiducci, Ennio Giulio Favalli, Fabrizio Conti, Elisa Gremese, Florenzo Iannone, Roberto Caporali, Marco Sebastiani, Gian Franco Ferraccioli, Giovanni Lapadula, Fabiola Atzeni

Summary: Axial spondyloarthritis (axSpA) is a group of chronic rheumatic diseases primarily affecting the axial skeleton. It includes ankylosing spondylitis, reactive arthritis, arthritis/spondylitis associated with psoriasis (PsA), and arthritis/spondylitis associated with inflammatory bowel diseases (IBD). Pain is a common and important symptom of axSpA, which can progress to chronic pain and significantly impact the quality of life. The development of axSpA inflammation involves complex interactions between genetic, epigenetic, and environmental factors, as well as dysregulated immune responses. Inhibition of IL-23 and IL-17 has been explored as a potential therapeutic strategy for axSpA.

JOURNAL OF CLINICAL MEDICINE (2022)

Article Medicine, General & Internal

Evolution of Rheumatoid-Arthritis-Associated Interstitial Lung Disease in Patients Treated with JAK Inhibitors: A Retrospective Exploratory Study

Vincenzo Venerito, Andreina Manfredi, Antonio Carletto, Stefano Gentileschi, Fabiola Atzeni, Serena Guiducci, Marlea Lavista, Laura La Corte, Elisa Pedrollo, Arnaldo Scardapane, Caterina Tomassini, Bruno Frediani, Carlo Salvarani, Florenzo Iannone, Marco Sebastiani

Summary: The aim of this multicenter retrospective study was to investigate the effectiveness and safety of JAK-inhibitors (JAKi) in patients with rheumatoid arthritis (RA) and interstitial lung disease (ILD). The study suggests that JAKi therapy might be a safe therapeutic option for patients with RA-ILD in a short-term follow-up.

JOURNAL OF CLINICAL MEDICINE (2023)

Article Biochemistry & Molecular Biology

Immunogenicity and Safety of Adjuvanted Recombinant Zoster Vaccine in Rheumatoid Arthritis Patients on Anti-Cellular Biologic Agents or JAK Inhibitors: A Prospective Observational Study

Vincenzo Venerito, Pasquale Stefanizzi, Luca Cantarini, Marlea Lavista, Maria Grazia Galeone, Antonio Di Lorenzo, Florenzo Iannone, Silvio Tafuri, Giuseppe Lopalco

Summary: RA patients treated with JAK inhibitors or anti-cellular bDMARDS have an increased risk of herpes zoster (HZ). This prospective study assessed the immunogenicity and safety of the Adjuvanted Recombinant Zoster Vaccine (RZV) in RA patients on JAK inhibitors or anti-cellular bDMARDS. The results showed that RZV vaccination induced a similar immune response in RA patients compared to healthy controls, regardless of the treatment.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)

Review Rheumatology

AI am a rheumatologist: a practical primer to large language models for rheumatologists

Vincenzo Venerito, Emre Bilgin, Florenzo Iannone, Sedat Kiraz

Summary: Natural Language Processing (NLP) and Large Language Models (LLMs) such as GPT, ChatGPT, or LLAMA have gained significant attention recently. They have impacted finance, economics, and healthcare in terms of diagnostic/scoring systems. Additionally, academic life, particularly in the field of rheumatology, is also experiencing the opportunities and challenges brought by NLP and LLMs.

RHEUMATOLOGY (2023)

Review Medicine, General & Internal

Rheumatoid Arthritis from Easy to Complex Disease: From the 2022 GISEA International Symposium

Simone Perniola, Maria Sole Chimenti, Francesca Romana Spinelli, Bruno Frediani, Rosario Foti, Sara Ferrigno, Cristina Garufi, Giulia Cassone, Vincenzo Venerito, Fabiola Atzeni, Roberto Caporali, Fabrizio Conti, Ennio Giulio Favalli, Florenzo Iannone, Marco Sebastiani, Gian Franco Ferraccioli, Giovanni Lapadula, Elisa Gremese

Summary: Rheumatoid Arthritis (RA) is a complex disease with various clinical phenotypes, categorized by disease duration, seropositivity for rheumatoid factor (RF) and/or anti-citrullinated protein antibodies (ACPA), joint subtype, clinical behavior, and other subgroups. This review provides a summary of the multifaceted aspects of RA, specifically focusing on the association between autoimmune status and clinical outcomes, achievement of remission, and treatment response, as discussed in the 2022 International GISEA/OEG Symposium.

JOURNAL OF CLINICAL MEDICINE (2023)

Article Rheumatology

Effectiveness of biological targeted therapies may discriminate seronegative from seropositive rheumatoid arthritis

Florenzo Iannone, Giuseppe Lopalco, Fabio Cacciapaglia, Vincenzo Venerito, Simone Perniola, Marco Fornaro

Summary: This study aimed to evaluate the effectiveness of bDMARDs in RA patients negative for RF and ACPA. The results showed that tocilizumab had a higher survival rate compared to abatacept in RF/ACPA negative RA patients.

RHEUMATOLOGY (2023)

No Data Available